Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Bolt Biotherapeutics

BOLT
Current price
0.76 USD -0.039 USD (-4.90%)
Last closed 0.79 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 30 120 884 USD
Yield for 12 month -55.51 %
1Y
3Y
5Y
10Y
15Y
BOLT
21.11.2021 - 28.11.2021

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California. Address: 900 Chesapeake Drive, Redwood City, CA, United States, 94063

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

1.25 USD

P/E ratio

Dividend Yield

Current Year

+7 876 000 USD

Last Year

+5 729 000 USD

Current Quarter

+5 274 000 USD

Last Quarter

+2 089 000 USD

Current Year

+5 992 000 USD

Last Year

+838 000 USD

Current Quarter

+4 816 000 USD

Last Quarter

+1 592 000 USD

Key Figures BOLT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -74 342 000 USD
Operating Margin TTM -946.19 %
PE Ratio
Return On Assets TTM -24.57 %
PEG Ratio
Return On Equity TTM -48.69 %
Wall Street Target Price 1.25 USD
Revenue TTM 7 876 000 USD
Book Value 2.96 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 48.1 %
Dividend Yield
Gross Profit TTM 1 620 000 USD
Earnings per share -1.66 USD
Diluted Eps TTM -1.66 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BOLT

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BOLT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation BOLT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 270.646
Price Sales TTM 5.8092
Enterprise Value EBITDA 0.4974
Price Book MRQ 0.3991

Financials BOLT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BOLT

For 52 weeks

0.73 USD 1.81 USD
50 Day MA 1.14 USD
Shares Short Prior Month 2 117 807
200 Day MA 1.09 USD
Short Ratio 18.95
Shares Short 2 132 225
Short Percent 6.94 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

430.32 USD Microsoft Corporation +0.69 (+0.16%)
Detailed analytics

ETF funds


S

SX7EEX

14.75 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics